Therapeutic apheresis before and after kidney transplantation

Journal of Clinical Apheresis

Volumn 26, Issue 5, 2011, Pages 252-260

  George, Sajid M ^a   Balogun, Rasheed A ^a   Sanoff, Scott L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

anti HLA antibodies; antibody medicated rejection; donor specific antibodies (DSA); incompatible transplantation; sensitization

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; COMPLEMENT COMPONENT C4D; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DONOR SPECIFIC ANTIBODY; GLUCOCORTICOID; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLASMA PROTEIN; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIBODY BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; APHERESIS; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; COMPLEMENT DEPENDENT CYTOTOXICITY; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY TEST; DESENSITIZATION; DRUG MEGADOSE; FLOW CROSSMATCH; FLOW CYTOMETRY; FOLLOW UP; GRAFT SURVIVAL; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE SYSTEM; HEMODIALYSIS; HLA MATCHING; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL PROCEDURES; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LAW; LIFE EXPECTANCY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN DONOR; PLASMAPHERESIS; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; RENAL REPLACEMENT THERAPY; REVIEW; SENSITIZATION; SOLID PHASE HLA ANTIBODY TEST; SPLENECTOMY;

ABO BLOOD-GROUP SYSTEM; ADSORPTION; ANTIBODIES; BLOOD COMPONENT REMOVAL; BLOOD GROUP INCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; THERAPEUTICS; TREATMENT OUTCOME;

EID: 80054052498     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20297     Document Type: Review

References (33)

1. Lindholm B, Davies S,. End-stage renal disease in 2010: timing of dialysis initiation and choice of dialysis modality. Nat Rev Nephrol 2011; 7: 66-68.
2. Hanna KE,. Biomedical politics. Institute of Medicine (US) Committee to Study Biomedical Decision Making. National Academy Press: Washington, DC, 1991.
3. U.S. Renal Data System. Atlas of End-Stage Renal Disease in the United States. USRDS. 2010. Annual Data Report 2009. Avilable online at.
4. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK,. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
5. Williams GM, Hume DM, Hudson RP Jr., Morris PJ, Kano K, Milgrom F,. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968; 279: 611-618.
6. Patel R, Terasaki PI,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
7. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
8. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K,. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
9. Racusen LC, Haas M,. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol 2006; 1: 415-420.
10. Kale-Pradhan PB, Woo MH,. A review of the effects of plasmapheresis on drug clearance. Pharmacotherapy 1997; 17: 684-695. (Pubitemid 27318962)
11. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J,. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262. (Pubitemid 39578859)
12. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J,. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIG). Am J Transplant 2002; 2: 758-760. (Pubitemid 36342618)
13. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, Kamil E, Tyan D,. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631-636. (Pubitemid 37071992)
14. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251. (Pubitemid 352008439)
15. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC,. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
16. Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Willingham DL, Taner CB, Hewitt WR, Grewal HP, Nguyen JH, Hughes CB, Gonwa TA,. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 87: 227-232.
17. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I,. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148. (Pubitemid 40095139)
18. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Buhler R, Vaughan RW, O'Donnell PJ, Snowden SA, Bewick M, Hendry BM,. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208-1211. (Pubitemid 26361608)
19. Sonnenday CJ, Ratner LE, Zachary AA, Burdick JF, Samaniego MD, Kraus E, Warren DS, Montgomery RA,. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34: 1614-1616.
20. Montgomery RA, Zachary AA,. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535-542. (Pubitemid 40052349)
21. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351. (Pubitemid 43382170)
22. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S,. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 2008; 86: 96-103.
23. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J,. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87: 268-273.
24. Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M,. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536-542.
25. Hume DM, Merrill JP, Miller BF, Thorn GW,. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955; 34: 327-382.
26. Tydén G, Donauer J, Wadström J, Kumlien G, Wilpert J, Nilsson T, Genberg H, Pisarski P, Tufveson G,. Implementation of a protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation 2007; 83: 1153-1155. (Pubitemid 46743673)
27. Fuchinoue S, Ishii, Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A, Koyama I, Kubota K, Tojimbara T, Nakajima I, Teraoka S,. The 5-year outcome of ABO-incompatible kidney transplantation with rituximad induction. Transplantation 2011; 91: 853-857.
28. Singh N, Pirsch J, Samaniego M,. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev 2009; 23: 34-46.
29. Mauiyyedi S, Crespo M, Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Tolkoff-Rubin NE, Williams WW, Delmonico FL, Cosimi AB, Colvin RB,. Acute humoral rejection in kidney transplantation. II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787. (Pubitemid 34183946)
30. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE,. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334-341. (Pubitemid 32055242)
31. Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Collins AB, Fitzpatrick D, Farrell ML, Williams WW, Delmonico FL, Cosimi AB, Colvin RB, Saidman SL,. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658. (Pubitemid 32268068)
32. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ,. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 2009; 41: 3690-3692.
33. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C,. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIG in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.